Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping
blood flow to the tumor.
PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without
thalidomide in treating patients who have metastatic prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)